Alector, Inc Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
January 06, 2020 at 08:30 am EST
Share
Alector, Inc. announced that in December 2019, it initiated dosing in healthy volunteers in its Phase 1 study of AL101, an investigational product candidate designed to increase progranulin levels. The Phase 1 study is designed to assess the safety and tolerability of AL101 in healthy volunteers, as well as the pharmacokinetics (PK), pharmacodynamics (PD) and bioavailability of intravenously and subcutaneously administered doses of AL101. AL101 is Alector’s second product candidate targeting the progranulin pathway to enter the clinic in the last two years. The Phase 1 study of AL101 is a randomized, double-blind, placebo-controlled trial expected to enroll up to 42 healthy volunteers at a clinical study site in the United States. The ClinicalTrials.gov Identifier for the AL101 study is: NCT04111666.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimerâs disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
ALECTOR, INC. 
